Skip to main
WVE

WVE Stock Forecast & Price Target

WVE Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Wave Life Sciences is a clinical-stage biotechnology company with a positive outlook due to its innovative PRISM platform, which combines multiple modalities and deep insights into human genetics to develop RNA medicines for rare and prevalent disorders. Despite the shifting competitive landscape, the company's lead programs in rare diseases have shown promising results, and its FDA-confirmed accelerated-approval pathway provides a clear development roadmap. Moreover, with a strong financial position and a diverse pipeline, Wave has the potential for long-term growth and could be an attractive partner for commercialization.

Bears say

Wave Life Sciences is a clinical-stage biotechnology company that utilizes RNA medicines to target and treat various diseases. However, the recent data shared at the American Thoracic Society Conference (ATS) was underwhelming, with WVE-006 showing lower total AAT levels compared to other competitors in the market. Additionally, the company's commercial landscape is becoming increasingly crowded, and its composite biomarker package remains unvalidated. With uncertainties regarding its regulatory path and potential competition, we have a negative outlook on the stock.

WVE has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Wave Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Wave Life Sciences Inc (WVE) Forecast

Analysts have given WVE a Buy based on their latest research and market trends.

According to 13 analysts, WVE has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Wave Life Sciences Inc (WVE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.